In silico analyses likely indicate quercetin as a CDK2 inhibitor in ER+ breast cancer [191] and that quercetin can re-sensitize breast cancer cells to palbociclib by governing the circHIAT1/miR-19a-3p/CADM2 axis. This evidence concerns the gene CDK2 and breast cancer.